首页> 美国卫生研究院文献>Oncotarget >Efficacy and safety of buparlisib a PI3K inhibitor in patients with malignancies harboring a PI3K pathway activation: a phase 2 open-label single-arm study

【2h】

Efficacy and safety of buparlisib a PI3K inhibitor in patients with malignancies harboring a PI3K pathway activation: a phase 2 open-label single-arm study

机译：PI3K抑制剂buparlisib在具有PI3K途径激活的恶性肿瘤患者中的有效性和安全性：2期开放性单臂研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Phosphatidylinositol 3-kinase (PI3K) pathway activation plays a key role in tumorigenesis and has been associated with poor prognosis and resistance to multiple therapies in various cancers.

机译：磷脂酰肌醇3-激酶（PI3K）途径激活在肿瘤发生中起关键作用，并已与各种癌症的不良预后和对多种疗法的耐药性相关。

著录项

期刊名称 Oncotarget
作者
Sarina A. Piha-Paul; Matthew H. Taylor; Daniel Spitz; Lee Schwartzberg; J. Thaddeus Beck; Todd M. Bauer; Funda Meric-Bernstam; Das Purkayastha; Linda Karpiak; Sebastian Szpakowski; Fadi Braiteh;
展开▼
作者单位

展开▼
年(卷),期 2019(10),60
年度 2019
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;细胞生物学;
关键词
phosphatidylinositol 3-kinase pathway; buparlisib; advanced malignancies; molecular selection; tissue agnostic;

机译：磷脂酰肌醇3-激酶途径;布帕西布;高级恶性肿瘤;分子选择;组织不可知;

相似文献

外文文献
中文文献
专利

1. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer Results from the Phase II BASALT-1 Study [J] . Vansteenkiste Johan F., Canon Jean-Luc, De Braud Filippo, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第9期

机译：II期BASALT-1研究的结果显示，布帕替尼（BKM120）在PI3K途径激活的非小细胞肺癌患者中的安全性和有效性
2. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial [J] . Wen Patrick Y., Touat Mehdi, Alexander Brian M., Journal of Clinical Oncology . 2019,第9期

机译：患有磷脂酰肌醇3-激酶途径的患者患者的Buparlisib：开放标签，多中心，多臂，II期试验
3. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway [J] . Rubinstein Maria M., Hyman David M., Caird Imogen, Cancer: A Journal of the American Cancer Society . 2020,第6期

机译：LY3023414在PI3K途径中患有激活突变患者患者中LY3023414的研究
4. Label-free phosphoproteomics method to investigate signaling pathways downstream of novel PI3K/mTOR inhibitors in cancer cells [C] . Pedro Casado, Juan Carlos Rodriguez-Prados, Sabina Cosulich, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：无标记的磷蛋白质方法，用于研究新型PI3K / MTOR抑制剂在癌细胞中的信号通路
5. Activation of the PI3K /Akt and beta-catenin pathways by Epstein -Barr virus latent membrane protein 2A in epithelial cells and in EBV-associated malignancies. [D] . Morrison, Jennifer A. 2004

机译：爱泼斯坦-巴尔病毒潜伏膜蛋白2A在上皮细胞和与EBV相关的恶性肿瘤中激活PI3K / Akt和β-catenin途径。
6. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label Multicenter Multi-Arm Phase II Trial [O] . Patrick Y. Wen, Mehdi Touat, Brian M. Alexander, -1

机译：布巴列布治疗复发性胶质母细胞瘤患者的磷脂酰肌醇3-激酶途径激活：一项开放标签多中心多臂II期试验
7. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer Results from the Phase II BASALT-1 Study [O] . Vansteenkiste Johan F., Canon Jean-Luc, De Braud Filippo, 2015

机译：BASALT-1 II期研究结果显示，buparlisib（BKM120）在PI3K途径激活的非小细胞肺癌患者中的安全性和有效性

Efficacy and safety of buparlisib a PI3K inhibitor in patients with malignancies harboring a PI3K pathway activation: a phase 2 open-label single-arm study

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅